These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 19024280)

  • 21. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

  • 22. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.
    Lindgren P; Geborek P; Kobelt G
    Int J Technol Assess Health Care; 2009 Apr; 25(2):181-9. PubMed ID: 19331709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rituximab in rheumatoid arthritis following anti-TNF-associated tuberculosis.
    Burr ML; Malaviya AP; Gaston JH; Carmichael AJ; Ostör AJ
    Rheumatology (Oxford); 2008 May; 47(5):738-9. PubMed ID: 18375402
    [No Abstract]   [Full Text] [Related]  

  • 24. Current aspects of anti-CD20 therapy in rheumatoid arthritis.
    Jacobi AM; Dörner T
    Curr Opin Pharmacol; 2010 Jun; 10(3):316-21. PubMed ID: 20189875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies.
    Kievit W; Fransen J; Adang EM; Kuper HH; Jansen TL; De Gendt CM; De Rooij DJ; Brus HL; van de Laar MA; Van Riel PC
    Ann Rheum Dis; 2009 Jun; 68(6):844-9. PubMed ID: 18625616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Biopharmaceuticals in the treatment of rheumatoid arthritis].
    Baslund B; Bendtzen K
    Ugeskr Laeger; 2008 Jun; 170(24):2108-10. PubMed ID: 18572481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of rheumatoid arthritis with rituximab: an update and possible indications.
    De Vita S; Quartuccio L
    Autoimmun Rev; 2006 Aug; 5(7):443-8. PubMed ID: 16920570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients.
    Popa C; van Tits LJ; Barrera P; Lemmers HL; van den Hoogen FH; van Riel PL; Radstake TR; Netea MG; Roest M; Stalenhoef AF
    Ann Rheum Dis; 2009 Jun; 68(6):868-72. PubMed ID: 18635596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis.
    Roll P; Palanichamy A; Kneitz C; Dorner T; Tony HP
    Arthritis Rheum; 2006 Aug; 54(8):2377-86. PubMed ID: 16869000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment.
    Roll P; Dörner T; Tony HP
    Arthritis Rheum; 2008 Jun; 58(6):1566-75. PubMed ID: 18512772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An update on pharmacogenomics in rheumatoid arthritis with a focus on TNF-blocking agents.
    Ranganathan P
    Curr Opin Mol Ther; 2008 Dec; 10(6):562-7. PubMed ID: 19051134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment strategy for rheumatoid arthritis in Croatia].
    Curković B
    Reumatizam; 2008; 55(2):39-44. PubMed ID: 19024273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation.
    Teng YK; Levarht EW; Toes RE; Huizinga TW; van Laar JM
    Ann Rheum Dis; 2009 Jun; 68(6):1011-6. PubMed ID: 18647852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
    Goldblatt F; Isenberg DA
    Handb Exp Pharmacol; 2008; (181):163-81. PubMed ID: 18071946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade.
    Manadan AM; Block JA
    Am J Ther; 2008; 15(1):53-8. PubMed ID: 18223354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis.
    Vos K; Thurlings RM; Wijbrandts CA; van Schaardenburg D; Gerlag DM; Tak PP
    Arthritis Rheum; 2007 Mar; 56(3):772-8. PubMed ID: 17328049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rituximab: new indication. In rheumatoid arthritis: for a few patients, with close monitoring.
    Prescrire Int; 2007 Oct; 16(91):186-8. PubMed ID: 17926823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. B cell-directed therapy in rheumatoid arthritis--clinical experience.
    Panayi GS
    J Rheumatol Suppl; 2005 Feb; 73():19-24; discussion 29-30. PubMed ID: 15693112
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
    Fautrel B; Guillemin F; Meyer O; de Bandt M; Berthelot JM; Flipo RM; Lioté F; Maillefert JF; Wendling D; Saraux A; Combe B; Le Loët X; ; ;
    Arthritis Rheum; 2009 Apr; 61(4):425-34. PubMed ID: 19333993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Panel discussion on B cells and rituximab: mechanistic aspects, efficacy and safety in rheumatoid arthritis and non-Hodgkin's lymphoma.
    Panayi GS; Hainsworth JD; Looney RJ; Keystone EC
    Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii18-ii20. PubMed ID: 15851523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.